United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

7 Dec 2016
Change (% chg)

¥-18 (-0.76%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for 4568.T


DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the... (more)


Beta: 0.82
Market Cap(Mil.): ¥1,683,193.00
Shares Outstanding(Mil.): 709.01
Dividend: 35.00
Yield (%): 2.74


  4568.T Industry Sector
P/E (TTM): 26.77 30.14 30.77
EPS (TTM): 88.69 -- --
ROI: 3.71 15.85 15.23
ROE: 4.99 16.96 16.56

BRIEF-Portola Pharmaceuticals expands pact with Daiichi Sankyo

* Portola Pharmaceuticals expands clinical collaboration agreement with Daiichi Sankyo worth up to $25 million to develop ANDEXXA (Andexanet Alfa) in Germany

Nov 01 2016

BRIEF-Pieris Pharmaceuticals to receive GLP Tox payment in Daiichi Sankyo collaboration

* Pieris Pharmaceuticals to receive GLP tox milestone payment in Daiichi Sankyo collaboration

Oct 26 2016

BRIEF-Daiichi Sankyo Co and Inspirion Delivery Sciences LLC Announce U.S. Licensing Agreement for MorphaBond

* Daiichi And Inspirion Delivery Sciences LLC announce U.S. Licensing agreement for morphabond formulated with sentrybond abuse-deterrent technology

Oct 25 2016

BRIEF-Daiichi Sankyo completes 20.2 mln shares' buy-back for 50 bln yen

* Says it completes around 20.2 million shares' buy-back for approximately 50 billion yen as of Oct. 24

Oct 24 2016

BRIEF-Daiichi Sankyo Co Ltd, Dana-Farber Cancer Institute today announce lung cancer research collaboration

* Daiichi Sankyo Co Ltd - co, Dana-Farber Cancer Institute today announced a preclinical research collaboration focused on lung cancer

Oct 12 2016

BRIEF-Daiichi Sankyo begins enrollment for late-stage trial testing Quizartinib in leukemia patients

* Daiichi Sankyo Co Ltd - first patient has been enrolled in global phase 3 quantum-first study evaluating oral FLT3-ITD inhibitor quizartinib

Oct 11 2016

Daiichi Europe execs need not testify in Benicar MDL - judge

By Brendan Pierson Japanese drugmaker Daiichi Sankyo Co Ltd does not have to produce two managers from its European affiliate for deposition in a multidistrict litigation claiming its blood pressure drug Benicar causes severe gastrointestinal problems, a federal magistrate judge has ruled.

Oct 05 2016

BRIEF-Daiichi Sankyo Co enters into a collaboration with Agonox Inc

* Daiichi Sankyo and Agonox will collaborate on preclinical development of program of an undisclosed immuno-oncology target

Oct 04 2016

BRIEF-Daiichi Sankyo announces New Global Head of Development

* Daiichi Sankyo announces new global head of development Source text for Eikon: Further company coverage:

Sep 06 2016

BRIEF-Daiichi Sankyo plans 5th&6th series unsecured corporate bonds worth total 100 bln yen

* Says it plans to issue 5th series unsecured corporate bonds worth 75 billion yen, with coupon rate of 0.810 percent and maturity date on July 25, 2036

Jul 15 2016

Earnings vs. Estimates